

eTable 2. Additional Treatment^a of Study Eyes by Category of Type 1 ROP at Enrollment

	Zone I, any Stage with Plus Disease	Zone I, Stage 3 without Plus Disease	Zone II, Stage 2 or 3 with Plus Disease	All Eyes
Enrolled & Treated	33	19	61	113
No additional treatment	17 (52%)	5 (26%)	29 (48%)	51 (45%)
Additional Treatment Indication				
Severe ROP	8 (24%)	7 (37%)	16 (26%)	31 (27%)
Treatment failure	1 (3%)	1 (5%)	4 (7%)	6 (5%)
Early reactivation	1 (3%)	0 (0%)	3 (5%)	4 (4%)
Late reactivation	6 (18%)	6 (32%)	9 (15%)	21 (19%)
Persistent avascular retina	8 (24%)	7 (37%)	16 (26%)	31 (27%)

^aAdditional treatment following initial intravitreal bevacizumab included laser retinal photocoagulation or intravitreal bevacizumab at investigator discretion.